TUCSON, AZ--(Marketwired - Jan 12, 2015) -  CDEX Inc. (OTCQB: CDEX), a pioneering developer, manufacturer and distributor of patented, real-time chemical detection and validation technologies for the healthcare and security markets, today announced that it has posted to its corporate website a letter to its shareholders. In the letter, Jeffrey Brumfield, Chairman and CEO of CDEX, discusses the events of 2014 and provides insight into the upcoming year.

To read the shareholder letter in its entirety, please click on the following link: http://cdex-inc.com/investors/ceo-corner/.

About CDEX Inc.

Headquartered in Tucson, Arizona, CDEX is engaged in pioneering technological advancements in the field of chemical and medication detection and validation for the healthcare and security markets. CDEX's proprietary solutions are based on its patented Enhanced Photoemission Spectroscopy technology for substance verification, authentication and identification. They include the ValiMed™ Medication Validation System product line marketed to healthcare markets worldwide for use in combatting diversion of controlled substances and narcotics, as well as compounded liquid pharmaceuticals to help ensure patient safety, and the ID2™ product line marketed to the global security market for use in detecting illegal or illicit drugs in difficult-to-monitor, critical environments. For more information, please visit www.cdex-inc.com.